Reaction
Her2 Positive Breast Cancer reporting signals
As of the last recalculation, Her2 Positive Breast Cancer appears in 364 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is TRASTUZUMAB (PRR 512.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Trastuzumab | 229 | 512.7 | 514.4 |
| Pertuzumab | 117 | 362.2 | 363.8 |
| Ado-Trastuzumab Emtansine | 28 | 205.6 | 206.3 |
| Lapatinib | 16 | 61.6 | 61.7 |
| Docetaxel Anhydrous | 57 | 57.2 | 57.2 |
| Docetaxel | 57 | 57.2 | 57.2 |
| Paclitaxel (Aibumin-Bound) | 63 | 52.8 | 52.8 |
| Paclitaxel | 65 | 45.5 | 45.5 |
| Tranexamic Acid | 6 | 39.2 | 39.2 |
| Capecitabine | 53 | 38.6 | 38.6 |
| Goserelin | 8 | 34.8 | 34.8 |
| Doxorubicin | 41 | 29.5 | 29.5 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 17.2 | 17.2 |
| Abemaciclib | 5 | 14.5 | 14.5 |